Personalis (NASDAQ:PSNL) Price Target Raised to $12.00

Personalis (NASDAQ:PSNL) had its price objective lifted by Needham & Company LLC from $10.00 to $12.00 in a research report released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research analysts have also recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Thursday, January 22nd. Guggenheim raised their price objective on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. BTIG Research lifted their price objective on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. HC Wainwright boosted their target price on shares of Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Finally, Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a report on Saturday, January 31st. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $11.14.

Personalis Stock Performance

Shares of PSNL opened at $9.06 on Friday. The firm has a fifty day moving average of $8.83 and a 200-day moving average of $8.00. The company has a market cap of $947.95 million, a price-to-earnings ratio of -9.96 and a beta of 2.02. Personalis has a 1 year low of $2.83 and a 1 year high of $11.50.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.05. The firm had revenue of $17.35 million for the quarter, compared to the consensus estimate of $17.12 million. Personalis had a negative return on equity of 42.81% and a negative net margin of 116.69%. Analysts predict that Personalis will post -1.4 EPS for the current year.

Hedge Funds Weigh In On Personalis

Large investors have recently bought and sold shares of the stock. Legal & General Group Plc bought a new position in Personalis in the second quarter worth $30,000. International Assets Investment Management LLC acquired a new position in shares of Personalis in the 4th quarter valued at $31,000. Ameritas Investment Partners Inc. acquired a new position in shares of Personalis in the 2nd quarter valued at $34,000. BNP Paribas Financial Markets lifted its holdings in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after acquiring an additional 5,177 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Personalis by 184.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock valued at $44,000 after acquiring an additional 3,592 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Key Personalis News

Here are the key news stories impacting Personalis this week:

• Positive Sentiment: Analyst price-target upgrade — Needham raised its PSNL target from $10 to $12 and reiterated a “buy” rating, implying meaningful upside from the current price and signaling increased analyst confidence. Benzinga
• Positive Sentiment: Operational growth target — Management outlined a plan targeting ~170% clinical test-volume growth for 2026 and highlighted acceleration from reimbursement and its MRD (minimal residual disease) strategy, which, if realized, would drive revenue and margin scaling. Seeking Alpha: Clinical Test Volume Growth
• Positive Sentiment: Q4 outperformance vs. EPS estimates — Personalis reported a $0.26 loss per share, beating consensus by $0.05, and delivered revenue roughly in line to slightly above expectations, which supports the near-term stock uplift. Press Release / Q4 Results
• Neutral Sentiment: Earnings call and transcript available — Management commentary and the full Q4 2025 call transcript provide more color on reimbursement progress, MRD commercialization cadence and margin plans; these details will determine whether the growth targets are credible. Yahoo Finance: Q4 Earnings Call Transcript
• Neutral Sentiment: Media coverage / snapshot pieces summarize results and strategy but add little new detail beyond the company release and call. SeattlePI: Q4 Snapshot
• Negative Sentiment: FY2026 revenue guidance set below street expectations — Personalis guided to roughly $78–$80M for FY2026 versus a consensus near $81M, introducing downside risk to near-term estimates and valuation. Yahoo Finance: Full Year Results & Guidance
• Negative Sentiment: Elevated short interest and persistent losses — Short interest rose ~21% in February to ~12.5% of float (an 8.6-day ratio), while the company remains unprofitable with negative margins and ROE, increasing volatility and downside risk if execution slips. MarketBeat: Short Interest & Stock Data
• Negative Sentiment: Conflicting coverage on revenue beat/miss — Some outlets flagged a revenue miss while company/other reports show a slight revenue beat; this mixed narrative can amplify intraday moves as investors parse which data source is authoritative. Zacks: Q4 Loss / Revenue Comment

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.